AN ANALYSIS OF CADAVER DONOR AND KIDNEY BIOPSY PARAMETERS WITH CORRELATION TO TRANSPLANT OUTCOMES Martin Mozes MD, Mel Schwartz MD, Janis Orlowski MD Michael.

Slides:



Advertisements
Similar presentations
Defining Preimplantation Renal Allograft Quality Is biopsy: helpful or harmful? Michael J. Goldstein MD Director, Kidney/Pancreas Transplantation RMTI/Mount.
Advertisements

UNOS Region 8 MELD29 Trial Analysis of the Results
SRTR Transplant Benefit-Based Liver Allocation Robert M. Merion, MD, FACS OPTN/UNOS Liver Forum Atlanta, GA April 12, 2010.
Tuesday Case Conference May Biopsy finding LM –Glomeruli are normal in size to mildly enlarged Mild enlargement of the mesangial areas with occasional.
ESRD Registry Committee, Korean Society of Nephrology*
SHARP trial Study of Heart and Renal Protection : a randomised placebo-controlled trial The e ff ects of lowering LDL cholesterol with simvastatin plus.
FORECASTING ONE-YEAR RENAL ALLOGRAFT FUNCTION AND SURVIVAL Yuriy Yushkov 1, Nikolina Icitovic 1, Ruslan Fedkiv 1, and Michael J. Goldstein 1,2 (1)New York.
Does Preoperative Hemoglobin Value Predict Postoperative Cardiovascular Complications after Total Joint Arthroplasty? Kishor Gandhi MD, MPH, Eugene Viscusi.
The Value of Zero-Hour Implantation Biopsies Volker Nickeleit Nephropathology Laboratory, Department of Pathology The University of North Carolina, Chapel.
Departments of Medicine and Biostatistics
Role of recurrent disease for late allograft loss Fernando G. Cosio Mayo Clinic, Rochester MN 10 th Banff conference on allograft pathology.
Superior outcomes in HIV-positive kidney transplant patients compared to HCV-infected or HIV/HCV co-infected recipients Deirdre Sawinski MD, Kimberly A.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
Calcineurin Inhibitor Toxicity In Kidney Allograft Protocol Biopsies Neeraja Kambham M.D. Stanford University.
Donor Organ Selection Criteria: What is Ideal? A Consensus (?) Discussion.
Recent management of Renal Transplantation in a Developing Country like Bangladesh, R Alam, Islam M S, R Alam, H Rahman, HU Rashid Department of Nephrology,
Extracorporeal Membrane Oxygenation Following Lung Transplantation in Adult ISKANDER AL-GITHMI, M.D., FRCSC, FRCSC (Ts & CDs), FCCP. Assistant Professor.
USRDS Clinical Indicators of Renal Allograft Loss Lawrence Y.C. Agodoa, MD FACP Jon J. Snyder, MS Bertram L. Kasiske, MD Allan J. Collins, MD FACP United.
Patient Survival USA Primary DD Pancreas Transplants 1/1/2004 – 12/31/2008 Categoryn 1Yr Surv. PTA % PAK1, % SPK4, % 2/09.
Assessment of Lupus (SLE) Mortality in a Patient-Based Community Data Bank Frederick Wolfe 1, Kaleb Michaud 1,2, Tracy Li 3, Robert S. Katz 4 1 National.
Allocation of elderly deceased donor kidneys Lisa Bradbury, Niaz Ahmad, Paul Gibbs, Richard Baker, Adam McLean, Chris Callaghan Renal Transplant Services.
David C. Mulligan, MD, FACS
Should Asymptomatic Patients Discharged with Lower Hemoglobin Expect Worse Outcomes After Valve Surgery? Niv Ad, MD Sari D. Holmes, PhD Alan M. Speir,
A Guide to the Scientific Registry of Transplant Recipients Organ Procurement Organization Reports
© ANZDATA Registry Method and Location of Dialysis 1453 (30%) 632 (13%) 1317 (27%) 1335 (27%) Number of Patients Australia 31-Dec-96.
INFLUENCE OF HLA MISMATCH ON GRAFT SURVIVAL IN RENAL TRASPLANTATION IN ADULTS IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo MD., Tagliafichi.
Proteinuria as a Surrogate in Kidney Disease In primary GN membranous nephropathy and focal and segmental glomerulosclerosis assocciated with the nephrotic.
1 Influence of donor & recipient risk factors and the choice of immunosuppression Long term outcome after renal transplantation Influence of donor & recipient.
Why don’t indigenous dialysis patients receive transplants – waitlist or allocation? N. Khanal 1, P. Clayton 1, S. McDonald 1, M. Jose 2 1 The University.
Risk of Osteoporotic Fractures Associated with Cumulative Exposure to Tenofovir and Other Antiretroviral Agents Roger Bedimo, MD; Song Zhang, PhD; Henning.
Living Donor Liver Transplantation in PSC Patients Giuliano Testa, MD, FACS, MBA Surgical Director, Living Donor Liver Transplantation Baylor University.
Irbesartan Diabetic Nephropathy Trial (IDNT) Collaborative Study Group N Eng J Med 345: , 2001 Edmund J. Lewis, M.D. Muehrcke Family Professor of.
PATIENT-GRAFT SURVIVAL ANALYSIS IN KIDNEY TRASPLANT WITH DECEASED DONOR IN CHILDREN IN ARGENTINA Bisigniano Liliana MD., López-Rivera Arturo.
Study of cytokine gene polymorphism and graft outcome in live-donor kidney transplantation By Rashad Hassan MD Amgad El-Agroudy, Ahmad Hamdy, Amani Mostafa.
The Expanded Criteria Donors in Kidney Transplantation: 3 Years Experience FAM Shaheen, B. Al-Attar, MZ Souqiyyeh, J.E Cillo, A. Al Sayyari.
Multicenter Study of Down-staging of Hepatocellular Carcinoma (HCC) to within Milan Criteria before Liver Transplantation Neil Mehta, MD; Jennifer Guy,
Factors Affecting Long-term First Renal Graft Survival Identified in a 10-year, 5-centre Retrospective National Study James Medcalf, John Bankart and Julie.
The Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial ONTARGET.
on behalf of the ACOSOG Z4032 Investigators
Survival after graft failure Dr Lynsey Webb Registrar UK Renal Registry UK Renal Registry 2011 Annual Audit Meeting.
Table 1. Clinicopathological findings at biopsy Clinical Number of patients Age (years) Gender (%Male) eGFR (ml/min/1.73m 2 ) UPE (g/day) Serum albumin.
HEART TRANSPLANTATION Pediatric Recipients 2014 JHLT Oct; 33(10):
2015 ANNUAL DATA REPORT V OLUME 2: E ND -S TAGE R ENAL D ISEASE Chapter 7: Transplantation.
LUNG TRANSPLANTATION Adult Recipients 2014 JHLT Oct; 33(10):
1 Statistical Review of the Observational Studies of Aprotinin Safety Part II: The i3 Drug Safety Study CRDAC and DSaRM Meeting September 12, 2007 P. Chris.
Histological markers of CNI nephrotoxicity: Specific or not specific? Marion Rabant MD, Renaud Snanoudj MD, Virginie Royal MD, C. Girardin, E.Morelon MD.
Lymph Node (LN) Ratio (LNR) Based Risk Classification (RC) in Stage III Colon Cancer (CC) with Internal and External Validation: Finding from the ACCENT.
CV-1 Trial 709 The ISEL Study (IRESSA ® Survival Evaluation in Lung Cancer) Summary of Data as of December 16, 2004 Kevin Carroll, MSc Summary of Data.
Results Methods Abstract Number 69 Objectives 1.Nephrol Dial Transplant (2011) 26: 537–543 2.J Support Oncol 2011;9:149–155 3.N Engl J Med. 2009; 361:1627–1638.
Quebec experience from 2003 to 2009 M Carrier MD, JF Lize MD and Quebec transplant programs Impact of Expanded Criteria Donors on outcomes of recipients.
Making the Most at the Margins Improving Organ Utilization and Recipient Outcomes. Jared C Brandenberger MD UNOS Region 6 Educational Forum March 6, 2015.
Impact of Recipient and Donor Non-immunological factors on the Outcome of Expanded Criteria Deceased Donors Kidney Transplantation Dr Hajar Al Hayyan.
D. Serón Nephrology Department Hospital Vall d’Hebron Barcelona Interpretation of sequential protocol biopsies in terms of prognosis and clinical implications.
소화기내과 김경엽 Gastroenterology 2011;140:
INTRODUCTION. The annual incidence of liver transplant outcomes in South America has been unknown. So far direct correlations have been reported between.
USRDS 2000 ADR USRDS Cadaveric donations by gender & race figure 7.1, patients aged
Single IMA {Single Arterial}
BUONA FUNZIONE RENALE DEI TRAPIANTI RENALI DA DONATORI ANZIANI VALUTATI CON CLEARANCE DELLA CREATININA SECONDO GAULT-COCKCROFT, CON DATI ECOGRAFICI E CON.
Living Donor Transplants
2016 Annual Data Report, Vol 2, ESRD, Ch 4
Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
LUNG TRANSPLANTATION Pediatric Recipients ISHLT 2010
Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial Michael J. Mack, MD.
HEART TRANSPLANTATION
Atlantic Cardiovascular Patient Outcomes Research Team
Post-transplant membranous glomerulonephritis as a manifestation of chronic antibody-mediated rejection Hyeon Joo Jeong, Beom Jin Lim, Myoung Soo Kima,
Volume 71, Issue 12, Pages (June 2007)
Number of Donors in Australia
Demographic Characteristics of Cohort
Presentation transcript:

AN ANALYSIS OF CADAVER DONOR AND KIDNEY BIOPSY PARAMETERS WITH CORRELATION TO TRANSPLANT OUTCOMES Martin Mozes MD, Mel Schwartz MD, Janis Orlowski MD Michael Harmon BSN, Ronald Skolek BSN Regional Organ Bank of Illinois and Rush Presbyterian -St. Lukes Medical center, Chicago IL. ARE WE DISCARDING KIDNEYS APPROPRIATELY ?

Background Proportion of kidneys from cadaveric donors over age 50 (“marginal donors”) has >doubled over 10 years to 30% of total. The kidney discard rate from “marginal” donors is >32%, double that of overall discard rates. Transplant outcomes with these kidneys is acceptable. There is a need to define factors leading to discard There is a need to validate the correctness of the decision to discard “marginal” kidneys.

Age % Increase (%) > (2.4)1,019 (8.8)385% ,294 (14.3)2,468 (21.2)91% ,535 (72.3)7,234 (62.1)10.7% < (11.0)924 (7.9)7.2% Total9,035 (100%)11,645 (100%)29% UNOS 2000 Annual Report Age Increase (%) > (2.4)1,019 (8.8)X ,294 (14.3)2,468 (21.2)X ,535 (72.3)7,234 (62.1) X 1.1 < (11.0)924 (7.9) X 0.9 Total9,035 ( 100%) 11,645 ( 100%) 29% UNOS 2000 Annual Report CADAVER DONOR AGE

Discard Rates after Recovery of Cadaveric Kidneys * Data through November 30,2000 SRTR

Donor Traits Associated with Kidney Graft Failure* Hazard Ratio Hypertensive, High Creatinine Hypertensive, Normal Creatinine Non-Hypertensive, High Creatinine Non- Hypertensive, Normal Creatinine Donor Age (years) * Deaths not due to graft failure were censored SRTR

Survival Benefit from Marginal Kidneys Days since transplantation (Equal time from wait-listing) Relative Risk (RR) of Death SRTR

PURPOSE of THE STUDY *To determine the ROBI kidney discard rates in Marginal Donors. *To determine donor and kidney biopsy factors associated with discard *To design a predictive score for kidney discard. *To validate the decision to discard.

Methods Data reviewed of all ROBI cadaver donors with kidney biopsy at ROBI during Kidney biopsy findings (Wedge-frozen and permanent) reviewed, graded and coded. Kidney recipients identified-with F/U 6M-5 years. Uni and multivariate analyses performed.

DISCARD RATES OF BIOPSIED KIDNEYS 539 DONORS (D) – 957 KIDNEYS (K) DISCARDS K (34%) BILATERAL BIOPSIES 418 D– 836 K DISCARDS – 305 K (36%) UNILATERAL BIOPSIES 121 D – 121K DISCARDS – 27 K (22%) DONORS WITH BIOPSY RELATED DISCARDS 361 D – 772 K DISCARDS: BILAT - 91 D UNILAT- 43 D NONE D ALL DISCARDS: 225 K (31%)

Donor Parameters-Bilateral Biopsies (N=361)* AGE: ( Range 3-82) GENDER: Male- 177(49%)Female- 184 (51%) RACE: C- 233(64.5%), AA- 96(26.6%), H-24(6.6%) O- 8 (2.2%) HTN: 175(48%) TREAT. HTN:136(38%) > 5 yrs. 85(49%) < 5 yrs.- 68 (39%) dur. unknown - 22(12%) DM: 31(8.8%) (IDDM -12, NIDDM -19) P.V.D.: 14 (4%) C.V.D: 24 (6.6%)*Biopsy related discards

DONOR PARAMETERS II (BILATERAL BIOPSIES*) S. CREAT.: ADMIT FINAL: GFR** :ADMIT FINAL PROTEINURIA: 0 -TRACE:60%; 1+:16%; 2+:14%; 3+:8%; 4+:0.6% DIC: 19 (5.3%) INTRA-OP FINDINGS: AORTIC PLAQUE: None-17%; Mild-40%; Mod.-19%;Severe-16% RENAL A. PLAQUE:None-44%; Mild-27%; Mod.-12%; Sev-11% CYSTS: None 80%; 1-2: 16%; >2: 17% ** Cockroft-Gault estimation*Biopsy related discards

Grading of Biopsy Findings 1. Glomerulosclerosis = % sclerotic glomeruli 2. *Atrophic cortical tubules 3. *Cortical Interstitial Fibrosis 4. *Arterial Lumen occluded by sub-intimal fibrosis 5. *Arterial Lumen occluded by sub-intimal hyalinosis *Semi-quantitated in quartiles and graded 1+ to 4+

FROZEN VS. PERMANENT SECTION READINGS COMPARISON BIOPSIES Median (25th, 75th percentiles ) FrozenPermanent # GLOMERULI35 (24, 51)43 (27, 63) # SCLEROTIC GLOMERULI 1 (0, 5)3 (0,8) % ATROPHIC CORT.TUBULES 1 (0, 1)1 (0,1) % INTERSTITIAL FIBROSIS 1 (0,1)1 (0,1) % ARTERIAL LUMEN OCCLUSION SUBINTIMAL FIBROSIS 0 (0,1)0 (0,1) HYALINOSIS 0 (0,1)0 (0,1) coding key : 0 = none, 1 = 1-25%, 2 = 26-50%, 3 = 51-75%, 4=76=100%

Donor Factors as Predictors of Kidney Discard Univariate Analysis for “all or some” kidneys transplanted Significant p<.05Not Significant AgeHeight RaceWeight Hx. HTNDonor Date Hx.Rx.HTNLupus Hx HTN> 5 yearsSCD Hx DMProteinuria Duration DMDIC CVD GFR (admit to final) Creat. Final GFR Admit GFR Final

Predictive Model For 2/2 KIDNEY USE (227/361) Age Points Under Race Caucasian 0.0 AA -1.1 Hispanic 0.2 Other -1.8 GFR final < GFR final > Hx. DM 0.0 No Hx HTN 1.6 O-Tr Prot 0.6 O-Mild A.Plaque pts=80% use and 5.6 pts>90% use AUC = 0.831

Predictive Model For 2/2 KIDNEY DISCARD (91/361) VariablePoints Age Under Race Caucasian 0.0 AA 1.1 Hispanic -0.8 Other 1.0 GFR final < GFR final > Hx DM 1.1 Hx Rx HTN 1.2 >4.2 Points.=>80% bilateral discard

Prediction models with Donor and Biopsy Parameters HxRxHTN.39 Creat.Final.53 Age.96 % GlomScl Art. Hyalinosis ODDS RATIOS.

Optimal* Predictive Ability - Donor and Biopsy Parameters *Using splines to fit each variable

Marginal Kidneys - Patient and Graft Survival

Graft Survival for ”Paired to Discard” Kidneys Recipient Characteristics (N=25*) Gender: M-18 F-7 Age: (34-67) DM: Yes-10 No-14 Race: C-13 AA-7 H-4 O-1 CIT: 27+8 hrs. MP- 9 S. Creat at 6 M *25/43 with complete data

summary The Kidney Discard rates in Marginal Donors is>30% Donor factors predictive of discard are age, race, GFR (admit and final),HTN and DM. Predictive Biopsy factors are: % Glomerulosclerosis and degree of Arteriolar hyalinosis. A highly accurate predictive score for kidney discard can be developed based on above factors. Kidneys paired to discarded kidneys result in acceptable outcomes when transplanted.

CONCLUSIONS Current transplant practices result in a high discard rate of “marginal donor” kidneys. Transplantation of kidneys similar to those currently being discarded results in acceptable outcomes. More wide spread application of innovative approaches will result in successful transplantation of many more patient: Two-for-one transplants. Alternate recipient lists for marginal kidneys. Accelerated placement protocols for marginal donors.